StockData
biote Corp. logo

biote Corp. (BTMD) stock

BTMDNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 8/3069% below fair value
$0.89−0.10 (-10.51%)

Close on Nov 18, 2026Market cap $31.83MP/E 8.9Yield –

biote operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

biote's operating income for the twelve months ending Jun 30, 2026 was $14.75M, down 58.3% year over year. For fiscal 2025 it was $35.55M, up 12.5% from the year before. The highest annual figure on record is $35.55M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$35.55M+12.5%
FY2024Dec 31, 2024$31.61M+10.3%
FY2023Dec 31, 2023$28.66M–
FY2022Dec 31, 2022-$60.72M-275.7%
FY2021Dec 31, 2021$34.56M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$3.51M-132.6%
Q1 FY2026Mar 31, 2026$3.17M-67.3%
Q4 FY2025Dec 31, 2025$6.83M+146.8%
Q3 FY2025Sep 30, 2025$8.27M-32.1%
Q2 FY2025Jun 30, 2025$10.77M+72.7%
Q1 FY2025Mar 31, 2025$9.69M-7.1%
Q4 FY2024Dec 31, 2024$2.77M-49.8%
Q3 FY2024Sep 30, 2024$12.18M+60.3%
Q2 FY2024Jun 30, 2024$6.23M-18.7%
Q1 FY2024Mar 31, 2024$10.43M+32.3%
Q4 FY2023Dec 31, 2023$5.51M-24.6%
Q3 FY2023Sep 30, 2023$7.60M-2.8%
Q2 FY2023Jun 30, 2023$7.67M–
Q1 FY2023Mar 31, 2023$7.88M-19.3%
Q4 FY2022Dec 31, 2022$7.30M+23.3%
Q3 FY2022Sep 30, 2022$7.82M-13.0%
Q2 FY2022Jun 30, 2022-$85.60M-934.3%
Q1 FY2022Mar 31, 2022$9.76M–
Q4 FY2021Dec 31, 2021$5.93M–
Q3 FY2021Sep 30, 2021$8.98M–
Q2 FY2021Jun 30, 2021$10.26M–
Q1 FY2021Mar 31, 2021-$107.88K–

More biote figures

See a number that looks wrong?